CLOSED
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i. Track Syngene International Limited's live NSE:SYNGENE share price ₹402.10 (+4.24%), market cap ₹₹162B, P/E 73.4. MarketRipple's AI analysis covers the investment thesis, ripple-chain impact, and Healthcare sector outlook for SYNGENE — real-time NSE India stock intelligence.
Open
₹386.50
High
₹403.70
Low
₹384.00
Prev. Close
₹385.75
52W High
₹709.50
52W Low
₹375.25
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i
Key Takeaway
Syngene International Limited is rated buy with a P/E of 73.4x — understand the valuation context before sizing a position.
★ Recommended
Ask AI: Is Syngene International Limited fairly valued right now?
Because a P/E of 73.4x needs to be compared against sector peers and growth expectations to be meaningful.
Continue Research
View events affecting Syngene International Limited
Because the investment case must account for macro and company-specific developments — events reveal the 'why' behind price moves.
Trace sector ripple effects
Because Healthcare moves create upstream and downstream implications that affect the entire thesis.
Intelligence Path
Growth
Govt Exposure
Policy Dependence
Execution Quality
News Sensitivity
Debt Strength
736 Cr
Revenue
-9 Cr
Net Profit
0%
ROE
0%
ROCE
5.48
EPS
| ₹ in Crore | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|
| Revenue | 3,080 | 3,370 | 3,513 | 3,611 | 3,563 |
| Net Profit | 464 | 510 | 496 | 317 | 241 |
| ROE (%) | — | — | — | 0.0% | 0.0% |
| EPS (₹) | — | — | — | 5.48 | 5.48 |
| Debt/Equity | — | — | — | 9.5 | 9.5 |